Mollugin as a Plant‐Derived Bioactive: Preclinical Pharmacology, Structure–Activity Relationships, Pharmacokinetic Evidence and Safety Requirements for Food–Health Translation

Mollugin is a naturally occurring naphthopyran compound isolated from Rubia cordifolia L. and other medicinal plants. Its diverse biological activities have attracted research interest, particularly in cancer‐related experimental models. This narrative review critically examines the phytochemistry, structure–activity relationships, preclinical pharmacology, pharmacokinetics, and toxicological evidence of mollugin, with emphasis on its potential relevance to food–health applications. Available pharmacological evidence is predominantly derived from in vitro studies and a limited number of animal models. Experimental findings indicate that mollugin modulates apoptosis, autophagy, ferroptosis, and signaling pathways associated with cell proliferation, survival, and drug resistance, including PI3K/Akt/mTOR, NF‐κB, HER2/Akt, and Notch‐related signaling. However, these observations do not establish clinical efficacy or direct molecular target specificity. Pharmacokinetic studies have quantified systemic exposure to mollugin following oral administration of multicomponent Rubia cordifolia preparations, but the absolute oral bioavailability of purified mollugin remains undetermined. Furthermore, available toxicological investigations are insufficient to establish a comprehensive safety profile or a safe dietary exposure range. Important evidence gaps include repeated‐dose toxicity, genotoxicity, reproductive and developmental toxicity, metabolic disposition, and potential interactions. No controlled human evidence currently supports the clinical efficacy or safety of mollugin. Consequently, its application as a functional‐food or nutraceutical ingredient remains hypothetical and requires rigorous evaluation of botanical quality, oral exposure, pharmacokinetics, and toxicological safety. Overall, mollugin represents a compound of preclinical pharmacological interest whose potential food–health applications require further experimental validation.

Authors

Institutions

Publication Details

Journal
Food Safety and Health
Published
2026-11-20
DOI
https://doi.org/10.1002/fsh3.70132
Primary Topic
Medicinal Plant Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Mollugin as a Plant‐Derived Bioactive: Preclinical Pharmacology, Structure–Activity Relationships, Pharmacokinetic Evidence and Safety Requirements for Food–Health Translation

Daniela Cornelia Călina, William N. Setzer, Javad Sharifi‐Rad, Ipek Peşin Süntar et al.
Food Safety and Health
Medicinal Plant Research
article

Mollugin as a Plant‐Derived Bioactive: Preclinical Pharmacology, Structure–Activity Relationships, Pharmacokinetic Evidence and Safety Requirements for Food–Health Translation

Daniela Cornelia Călina, William N. Setzer, Javad Sharifi‐Rad, Ipek Peşin Süntar, Hasya Nazlı Gök, Mert İlhan
article en

Abstract

Mollugin is a naturally occurring naphthopyran compound isolated from Rubia cordifolia L. and other medicinal plants. Its diverse biological activities have attracted research interest, particularly in cancer‐related experimental models. This narrative review critically examines the phytochemistry, structure–activity relationships, preclinical pharmacology, pharmacokinetics, and toxicological evidence of mollugin, with emphasis on its potential relevance to food–health applications. Available pharmacological evidence is predominantly derived from in vitro studies and a limited number of animal models. Experimental findings indicate that mollugin modulates apoptosis, autophagy, ferroptosis, and signaling pathways associated with cell proliferation, survival, and drug resistance, including PI3K/Akt/mTOR, NF‐κB, HER2/Akt, and Notch‐related signaling. However, these observations do not establish clinical efficacy or direct molecular target specificity. Pharmacokinetic studies have quantified systemic exposure to mollugin following oral administration of multicomponent Rubia cordifolia preparations, but the absolute oral bioavailability of purified mollugin remains undetermined. Furthermore, available toxicological investigations are insufficient to establish a comprehensive safety profile or a safe dietary exposure range. Important evidence gaps include repeated‐dose toxicity, genotoxicity, reproductive and developmental toxicity, metabolic disposition, and potential interactions. No controlled human evidence currently supports the clinical efficacy or safety of mollugin. Consequently, its application as a functional‐food or nutraceutical ingredient remains hypothetical and requires rigorous evaluation of botanical quality, oral exposure, pharmacokinetics, and toxicological safety. Overall, mollugin represents a compound of preclinical pharmacological interest whose potential food–health applications require further experimental validation.

Food Safety and Health
University of Medicine and Pharmacy of Craiova (RO), Universidad Espíritu Santo (EC), Aromatic Plant Research Center (US), Centro de Estudios Tecnológicos y Universitarios del Golfo (MX), Düzce Üniversitesi (TR), University of Alabama in Huntsville (US), Gazi University (TR)
Medicinal Plant Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon